Alera MT, Srikiatkhachorn A, Velasco JM, et al. Incidence of dengue virus infection in adults and children in a prospective longitudinal cohort in the Philippines. PLoS Negl Trop Dis. 2016;10:e0004337
Coudeville L, Baurin N, Shepard DS. The potential impact of dengue vaccination with, and without, pre-vaccination screening. Vaccine. 2020;38:1363-1369.
Sistema GAL-Nacional. Coordenação Geral de Laboratórios. Secretaria de Vigilância em Saúde.Ministério da Saúde. 2021. http://gal.datasus.gov.br/GAL/index.php?area=01. Accessed April 16, 2021.
Dayan GH, Langevin E, Gilbert PB, et al. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. Vaccine. 2020;38:3531-3536.
Guirakhoo F, Arroyo J, Pugachev KV, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever–dengue virus tetravalent vaccine. J Virol. 2001;75:7290-7304.
Guirakhoo F, Weltzin R, Chambers TJ, et al. Recombinant chimeric yellow fever–dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000;74:5477-5485.
Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29:7229-7241.
Guy B, Ooi EE, Ramos-Castañeda J, et al. When can one vaccinate with a live vaccine after wild-type dengue infection? Vaccines (Basel). 2020;8:174.
Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8:S7-S16.
Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195-1206.
Instituto Nacional de Salud. Boletín epidemiológico seminal. Semana epidemiológica 03: 17 al 23 de enero de 2021. https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2021_Boletin_epidemiologico_semana_3.pdf
Luo R, Fongwen N, Kelly-Cirino C, et al. Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews. Clin Microbiol Infect. 2019;25:659-666.
Nealon J, Bouckenooghe A, Cortes M, et al. Dengue endemicity, force of infection, and variation in transmission intensity in 13 endemic countries. Correction in: J infect Dis. 2020 July 15;222:341-342. J Infect Dis. 2020;jiaa132.
Pan American Health Organisation. PLISA Health Information Platform for the Americas. Dengue 2021. Accessed April 16, 2021. https://www.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en.html
Pediatric Infectious Disease Society of Thailand (PIDST). Guidance for the Use of Dengvaxia™️ by the Pediatric Infectious Diseases Society of Thailand and the Infectious Diseases Association of Thailand. Published December 26, 2017. Accessed April 16, 2021. http://english.pidst.net/A415.html
Secretaría de Salud. Panorama Epidemiológico de Dengue, Semana 53. Gobierno de México. 2020. https://www.gob.mx/cms/uploads/attachment/file/604556/Pano_dengue_53_2020.pdf
Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327-340.
Vandepitte WP, Chaweethamawat A, Yoksan S. Seroprevalence of neutralizing antibody against dengue virus in healthcare workers in Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 2019;50:816-824.
Wartel TA, Prayitno A, Hadinegoro SR, et al. Three decades of dengue surveillance in five highly endemic South East Asian countries. Asia Pac J Public Health. 2017;29:7-16.
Wilder-Smith A, Smith PG, Luo R, et al. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report. Vaccine. 2019;37:5137-5146.
World Health Organization (WHO). Dengue Control: Epidemiology. Updated December 22, 2016. Accessed April 16, 2021. https://www.who.int/denguecontrol/epidemiology/en/
World Health Organization (WHO). WHO Position Paper on Dengue Vaccines (2018). Accessed April 16, 2021. https://www.who.int/immunization/policy/position_papers/dengue/en/

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Marco Sáfadi, MD

Associate Professor of Pediatrics
Head of Department of Pediatrics
Santa Casa de São Paulo
School of Medical Sciences (FCMSCSP)
São Paulo, Brazil

Disclosures

Disclosure: Marco Sáfadi, MD, has the following relevant financial relationships:
Advisor or consultant for: Sanofi Pasteur; Takeda
Speaker or a member of a speakers bureau for: Sanofi Pasteur; Takeda
Grants for clinical research from: Sanofi Pasteur; Takeda

Faculty

João Bosco Siqueira, MD

Epidemiologist
Tropical Pathology and Public Health Institute
Associate Professor
Federal University of Goiás
Goiás, Brazil

Disclosures

Disclosure: João Bosco Siqueira, MD, has the following relevant financial relationships:
Advisor or consultant for: GlaxoSmithKline; Merck; Sanofi
Speaker or a member of a speakers bureau for: Sanofi Pasteur; Takeda
Grants for clinical research from: Sanofi Pasteur

Terapong Tantawichien, MD

Assistant Director
Queen Saovabha Memorial Institute
Thai Red Cross Society
Department of Medicine Chairman
Faculty of Medicine
Chulalongkorn University
Bangkok, Thailand

Disclosures

Disclosure: Terapong Tantawichien, MD, has the following relevant financial relationships:
Grants for clinical research from: Sanofi Pasteur

Editor

Rita Moreira da Silva, PhD, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Rita Moreira da Silva, PhD PharmD, has disclosed no relevant financial relationships.

CME/Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

The Many Faces of Dengue: Serotypes, Vaccine Coverage, and Serotesting for Optimal Patient Selection

Authors: Marco Sáfadi, MD; João Bosco Siqueira, MD; Terapong Tantawichien, MD
CPD Released: 5/28/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/28/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, pediatricians, and infectious disease/HIV specialists.

The goal of this activity is to improve prescreening for prior exposure to dengue to ensure that the broadest possible vaccine serotype coverage is available to eligible persons living in areas endemic for dengue.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Serotypes of dengue virus
- Proper use of pre-vaccination screening tools to optimize benefits and minimize the risks of dengue vaccination
Have greater competence related to
- The ability to communicate the concept of “screen and vaccinate” to patients

Disclosures

Moderator

Marco Sáfadi, MD

Associate Professor of Pediatrics
Head of Department of Pediatrics
Santa Casa de São Paulo
School of Medical Sciences (FCMSCSP)
São Paulo, Brazil

Disclosures

Disclosure: Marco Sáfadi, MD, has the following relevant financial relationships:
Advisor or consultant for: Sanofi Pasteur; Takeda
Speaker or a member of a speakers bureau for: Sanofi Pasteur; Takeda
Grants for clinical research from: Sanofi Pasteur; Takeda

Faculty

João Bosco Siqueira, MD

Epidemiologist
Tropical Pathology and Public Health Institute
Associate Professor
Federal University of Goiás
Goiás, Brazil

Disclosures

Disclosure: João Bosco Siqueira, MD, has the following relevant financial relationships:
Advisor or consultant for: GlaxoSmithKline; Merck; Sanofi
Speaker or a member of a speakers bureau for: Sanofi Pasteur; Takeda
Grants for clinical research from: Sanofi Pasteur

Terapong Tantawichien, MD

Assistant Director
Queen Saovabha Memorial Institute
Thai Red Cross Society
Department of Medicine Chairman
Faculty of Medicine
Chulalongkorn University
Bangkok, Thailand

Disclosures

Disclosure: Terapong Tantawichien, MD, has the following relevant financial relationships:
Grants for clinical research from: Sanofi Pasteur

Editor

Rita Moreira da Silva, PhD, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Rita Moreira da Silva, PhD PharmD, has disclosed no relevant financial relationships.

CME/Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape

From Medscape Education

CPD

The Many Faces of Dengue: Serotypes, Vaccine Coverage, and Serotesting for Optimal Patient Selection

Authors: Marco Sáfadi, MD; João Bosco Siqueira, MD; Terapong Tantawichien, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 5/28/2021

Valid for credit through: 5/28/2022, 11:59 PM EST

processing....

Pre-Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 4

CPD Information Download Slides

Activity Transcript

PDF Downloads

Transcript Downloads

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Marco Sáfadi, MD

Faculty

João Bosco Siqueira, MD

Terapong Tantawichien, MD

Editor

Rita Moreira da Silva, PhD, PharmD

CME/Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CPD

The Many Faces of Dengue: Serotypes, Vaccine Coverage, and Serotesting for Optimal Patient Selection

Target Audience and Goal Statement

Disclosures

Moderator

Marco Sáfadi, MD

Faculty

João Bosco Siqueira, MD

Terapong Tantawichien, MD

Editor

Rita Moreira da Silva, PhD, PharmD

CME/Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Many Faces of Dengue: Serotypes, Vaccine Coverage, and Serotesting for Optimal Patient Selection

Pre-Assessment Survey

PDF Downloads

Transcript Downloads